Consistently favorable safety profile1–21

ALECENSA has a well-established, manageable
safety profile1–21


The safety profile of ALECENSA has remained consistent across multiple clinical trials and real-world studies assessing a diverse range of patients.1–21


A consistent safety profile proven over 10 years

ALECENSA has a well-established, manageable
safety profile, as shown in the ALEX final analysis2,3

3068472_Alecensa25_Website_2_Images_V1

The safety profile
of ALECENSA remained consistent over a longer median
follow-up of
53.5 months, with no new or unexpected safety signals observed.3

The safety profile of ALECENSA remained consistent over a
longer median follow-up of 53.45 months, with no new or unexpected safety signals observed.3

Efficacy that translates into sustained QoL improvement in ALK+ advanced NSCLC22

Clinically meaningful improvement in HRQoL (≥10 point increase)*

5 months extension in HRQoL improvement vs. crizotinib22


Patients experienced longer lasting improvements in their symptoms with ALECENSA, including22:



Chest pain



Cough



Fatigue



Dyspnea



Pain in other areas 

Discover

 

alecensa provides a

reassuring experience >

*Changes in HRQoL and functioning were assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30.22

 

AE, adverse event; ALK, anaplastic lymphoma kinase; COD, cut-off date; HRQoL, health-related quality of life; NSCLC, non-small-cell lung cancer; PT, patient; QoL, quality of life.

 

1. Peters S, et al. N Engl J Med 2017;377:819–838. 2. Mok T, et al. Ann Oncol 2020;31:1056–1064. 3. Peters S, et al. Ann Oncol 2025. DOI: 10.1016/j.annonc.2025.09.018. 4. Wu YL, et al. N Engl J Med 2024;390:1265–1276. 5. Dziadziuszko R, et al. J Thorac Oncol 2021;16:2040–2050. 6. Gadgeel SM, et al. Ann Oncol 2023;34:S782–S783. 7. Wolf J, et al. ESMO Open 2022;7:100333. 8. Nakagawa K, et al. Lung Cancer 2020;139:195–199. 9. Novello S, et al. Annals Oncol 2018;29:1409–1416. 10. Arrieta O, et al. Nat Commun 2025;16:4553. 11. Barlesi F, et al. Ann Oncol 2016;27(Supplement 6):vi416–vi545. 12. Yang JCH, et al. Thorac Oncol 2017;12:1552–1560. 13. Ou SH, et al. J Clin Oncol 2016;34:661–668. 14. Shaw AT, et al. Lancet Oncol 2016;17:234–242. 15. Dziadziuszko R, et al. Updated results from the Phase III ALINA study of adjuvant alectinib vs chemotherapy in patients with early stage ALK+ non-small cell lung cancer (NSCLC). ESMO. 17–21 October 2025. Berlin, Germany. 16. ALECENSA Summary of Product Characteristics. 17. Zhou Z, et al. Transl Lung Cancer Res 2022;11:2495–2506. 18. DiBonaventura MD, et al. OncoTargets Ther 2018:11 75–82. 19. Hizal M, et al. Future Oncol 2022;18:2573–2582. 20. Masuda N, et al. Cancer Sci 2019;110:1401–1407. 21. Wang M, et al. Target Oncol 2023;18:571–583. 22. Perol M, et al. Lung Cancer 2019;138:79–87.

 

© 2025 F. Hoffmann-La Roche Ltd. M-XX-00021690; Date of preparation: December 2025 Legal Statement - Privacy Policy - Cookie Prefer